Latest Financials News

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Arafura Rare Earths has raised A$481 million in equity funding and secured key government backing, advancing its Nolans Project towards a final investment decision in 2026.

Diablo Resources reported a net cash outflow of A$456k for operating activities in the December 2025 quarter, offset partially by a A$2 million equity raise. Despite this, the company’s cash runway remains limited to about one quarter, prompting plans for further funding.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Fortuna Metals has confirmed significant high-grade rutile mineralisation at its newly acquired Mkanda project in Malawi, supported by a successful A$3.5 million capital raise to advance exploration.

Barton Gold Holdings has completed significant drilling upgrades and advanced feasibility studies across its South Australian projects, raising $15 million to support a targeted production restart by the end of 2026.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

Silver Mines Limited has reported its best-ever drilling results at the Bowdens Silver Project in NSW while navigating a complex regulatory redetermination process. Exploration advances continue across its Australian and US projects, supported by a strong cash position.